1 / 1

Inhaled Nicotine

Aradigm has product candidates addressing the treatment of non cystic fibrosis bronchiectasis, cystic fibrosis and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. Aradigm is also developing liposomal ciprofloxacin formulations as potential medications for patients with chronic lung infections with non tuberculous mycobacteria (NTM), and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, Q fever and inhaled anthrax.

aradigm
Download Presentation

Inhaled Nicotine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. January 8, 2015 Aradigm to Present at Biotech Showcase 2015 on January 14 HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present an overview of the Company at Biotech Showcase 2015 on Wednesday, January 14, 2015, at 2:30 p.m. Pacific time. The event will be held at Parc 55 Wyndham - Union Square Hotel, San Francisco, California. Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 14 days. About Aradigm Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of non-cystic fibrosis bronchiectasis, cystic fibrosis and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. Aradigm is also developing liposomal ciprofloxacin formulations as potential medications for patients with chronic lung infections with non-tuberculous mycobacteria (NTM), and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, Q fever and inhaled anthrax. More information about Aradigm can be found at www.aradigm.com. Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation. Aradigm Corporation Nancy Pecota, 510-265-8800 Chief Financial Officer Source: Aradigm Corporation News Provided by Acquire Media

More Related